Aachen. CRPS/Sudeck's disease was conducted by the pharmaceutical manufacturer Grünenthal, Aachen, to conduct a clinical study on the active ingredient neridronate. Neridronic acid) launched an aminobisphosphate. In various clinics in Germany, sufferers can take part in this clinical trial.
The studies will be conducted at sites in the US, Canada, Germany, France, the UK, Spain, Ukraine, the Czech Republic, Slovakia, Poland, Serbia, Australia, New Zealand and South Korea.
There are two placebo-controlled clinical trials that currently conduct and recruit patients. One also has clinical study centers in Germany where patients can be included in the study if they are eligible according to all inclusion/exclusion criteria.
Here's the link clinical trials.gov for this study: https://clinicaltrials.gov/ct2/show/NCT03530345?term=neridronic+acid&cond=CRPS&rank=1
The clinical study centers in Germany are:
Center for Clinical Research Dr. med. Medical. I. Schoel, Bad Homburg, tel: 06172/1710784
Clinical Research Berlin Mitte GmbH, Berlin, Tel: 030/206580-800
BAG anesthesia, pain therapy, palliative care, cottbus, tel: 03552/890785
Clinical Research Hamburg GmbH, Hamburg; Phone: 040/460763030
Clinical Research Hannover Mitte, Hanover, Tel: 0511/169765-0
Department and Department of Neurology University Medicine Mainz, Mainz, Tel: 0613iconfin0-2222
Clinical Research Schwerin GmbH, Schwerin, Tel: 0385/557740
Patients will need to contact the sites and potentially make an appointment to check suitability. Please note that an important criterion is that the CRPS duration from the onset of signs and symptoms is no more than 2 years. People with a longer CRPS duration cannot be considered.
Recruitment should continue until early 2020.
For inclusion in the clinical trial, there are various admission requirements named in the following document. There is also more information on the study. Contact can be made about this.
A position paper on the treatment of CRPS in Europe was published in the European Journal of Pain in January. Well-known medical practitioners from Great Britain, Germany, Switzerland, Belgium, the Netherlands, France, Denmark and Poland as well as from Irsael and Australia have together put together the current methods and best practices to raise standards for treatment Set. So far, there are different good and bad treatment routes in each country and the secured diagnosis "CRPS" is either not made or not made in time.
So far, we have only been present in English for the position paper, but we are working on a translation that we will publish here.
The CRPS network has translated the position paper into German for a better understanding. The translation can be downloaded here.
Dear people, Dear relatives, Dear friends, We just received a call from our friendly CRPS Association from Australia "CRPS Network australia" for their own worldwide study on "time to Diagnosis/treatment at CRPS". Since this survey is completely in english, we have translated it into German and also make it available. The collected data is then Merged. Excerpt from the accompanying text of the Survey:
This survey is aimed at people all over the world who have been diagnosed with the complex regional pain syndrome. To be able to participate, you must be 16 years or older (parents/guardians are encouraged to complete this survey on behalf of children under the age of 16 with CRPS diagnosis).
For this year's patient meeting in Aachen, the Global alliance of CRPS Global has been expanded to include two major countries: Australia with the CRPS Network Australia Spain with Sudeck.ES we are looking forward to the joint work and the European and world-wide exchange.
At the 18.05.2018, the Allianz CRPS global groups from Germany, the Netherlands, Spain and Australia met in Aachen to collaborate on drug research for CRPS, patient studies on disease and on the global cooperation of CRPS Patients ' organisations.
The groups from the United Kingdom and the United States unfortunately could not be present at this meeting. The results are, of course, shared among themselves. The aim of the meeting was mainly to find out how studies on CRPS could be raised and how to gain people affected for these studies. DANEBN was concerned with the further evaluation of own patient studies of patient organisations.